-Tehelka With 65 percent of the population below the age of 35, India boasts of an unparalleled generational dividend, but are we turning this potential into a disaster? Avalok Langer spots a ticking time bomb Nutrition & Health* 40% of children in India are malnourished 43% of children in the age group of 12-23 months receive full immunisation 48%+ of children are underweight 50%+ of all deaths under age 5 are related to malnutrition 45% of children...

-The Times of India MUMBAI: The urban Indian's diet, pickled with takeaways from fast-food joints and instant foods that are ready in a jiffy at the end of a long working day, could worsen the present epidemic of hypertension due to its high proportion of salt. In a city where every fourth adult is believed to have hypertension, experts said the focus should be on reducing salt intake in the daily...

-The Hindu Considering the knowledge of English as a mark of social advancement and that of the vernacular as backwardness disenfranchises significant sections of society In a village in Ghazipur district that borders Varanasi, there is a young man who teaches English and "personality development" to the sons and daughters of local shopkeepers, farmers and truck drivers. The classes are held from 6 to 8 in the morning and again in the...

-The Hindu The lesson from the Supreme Court ruling on Gleevec is that pharmaceutical multinational corporations need to focus research on genuine innovations rather than on ways to evergreen their patents The much awaited Supreme Court judgment on Gleevec has been delivered. Novartis has failed in reversing the rejection of its patent. And, predictably - like a scratched record - there have been suggestions that pharma investments in India will dry...

-The Economic Times Foreign pharma companies could be forced to overhaul their strategy for the Indian market by striking more local deals and cutting sky-high drug prices after the Supreme Court slammed the door on Swiss giant Novartis' attempts to gain a patent for its blood cancer-busting drug Glivec. But the ruling, welcomed by activists campaigning for affordable drugs and local generic companies, threatened to reinforce a narrative that India...